Cancer Clinical Decision Tools Market Poised for Robust Growth: Comprehensive Analysis Revealed in New Global Report [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
Unveiling the latest research report on the Cancer Clinical Decision Tools industry, highlighting significant growth, technological advancements, and the rise in global cancer incidence. In the ever-evolving realm of healthcare technology, the cancer clinical decision tools market has witnessed a surge in growth, expanding from $0.45 billion in 2023. Industry experts forecast continued expansion, with the market size expected to reach $0.5 billion in 2024, demonstrating an impressive 11.2% compound annual growth rate (CAGR). Innovative developments and the adoption of sophisticated healthcare solutions are driving this growth, reflecting an increasing need for personalized medicine and more effective cancer treatment strategies. Driving Factors Behind the Growing Demand Innovative technology propelling cancer diagnostics and treatment efficiencies. Rise in personalized medicine approaches customizing patient care. Influx of healthcare IT solutions optimizing patient outcome
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- NeoGenomics, Inc. (NASDAQ: NEO) had its price target lowered by analysts at BTIG Research from $23.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- NeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- NeoGenomics, Inc. (NASDAQ: NEO) had its price target lowered by analysts at TD Cowen from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $18.00 price target on the stock.MarketBeat
NEO
Earnings
- 4/30/24 - Beat
NEO
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- NEO's page on the SEC website